富智康(02038.HK)與Stellantis訂非約束性意向書
富智康(02038.HK)公布,於今日(18日)與汽車製造商及出行供應商Stellantis共同訂立了非約束性意向書,當中載列了根據荷蘭王國法律成立及經營的合營公司的合作框架及原則。
初始結構擬由富智康及Stellantis各自持有50%權益的合營控股公司來進行軟件及硬件業務。而該合營控股公司與其分別位於台灣及中國大陸開展軟件業務之全資附屬公司統稱為「合營集團」。
合營集團之初始業務範圍擬專注於車用資訊娛樂系統、車載通訊解決方案、雲端服務平台以及相關的配套硬件及軟件等領域。倘若合營協議未及於今年8月31日或之前簽立,富智康或Stellantis可向另一方發出書面通知並終止該意向書。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.